evipedia.ai
← Back

Phosphatidylinositol for Health & Longevity

Evidence Review created on 11/06/2026 using AI4L / Opus 5.5

Also known as: PI, PtdIns, Phosphatidyl Inositol, Phosphatidyl-myo-inositol, 1-Phosphatidyl-1D-myo-inositol, Soy Phosphatidylinositol, Soybean Phosphatidylinositol, CRD5

Motivation

Phosphatidylinositol is a fat-like molecule made of two fatty acids, phosphate and inositol, a ring-shaped sugar alcohol. It is part of every cell membrane and is the raw material for a small family of signaling fats that carry messages from insulin and other growth signals into the cell. Commercially it comes mainly from soybeans, where it is a minor part of lecithin.

Interest in taking it as a supplement came from a Canadian company that developed a purified soy preparation as a possible treatment for low levels of “good” cholesterol, and from Japanese animal studies of liver fat and metabolism. Because digestion releases part of its inositol, it is also linked to the separate and larger body of research on inositol supplements.

This review examines the human, animal and laboratory evidence on taking phosphatidylinositol for health and longevity: its proposed effects on blood fats, blood sugar control and the liver, its risks and interactions, the doses that have been studied, and who produced the evidence.

Benefits - Risks - Protocol - Conclusion

A podcast episode on PI3K (phosphoinositide 3-kinase, an insulin-activated enzyme that acts on phosphatidylinositol), and four narrative reviews that discuss phosphatidylinositol as a dietary or therapeutic agent, its lipid effects, or its inositol biology in depth.

No content from the other priority experts (FoundMyFitness, Huberman Lab, Chris Kresser, Life Extension, Lifespan.io) discusses PI; their related hits, a members-only FoundMyFitness Q&A and Huberman Lab episode segments, address free inositol rather than PI.

Grokipedia

Phosphatidylinositol

A biochemistry-focused entry covering PI’s structure, biosynthesis, conversion into signaling lipids and research history; it does not evaluate PI as a supplement.

Examine

No Examine article on phosphatidylinositol exists.

ConsumerLab

No ConsumerLab article on phosphatidylinositol exists.

Systematic Reviews

No systematic reviews or meta-analyses for Phosphatidylinositol were found on PubMed as of November 6, 2026.

Mechanism of Action

PI is a glycerophospholipid (a membrane fat built on glycerol) carrying two fatty acids and a phosphate-linked myo-inositol ring. Soy PI is rich in linoleic acid (an omega-6 fatty acid).

  • Signaling precursor: Cells phosphorylate PI into PIP2 (PI carrying two phosphates). Phospholipase C (a PIP2-splitting enzyme) releases IP3 (inositol trisphosphate, which frees stored calcium) and DAG (diacylglycerol, which activates protein kinase C, a protein-activating enzyme); PI3K converts PIP2 into PIP3 (a three-phosphate form that drives growth signaling).
  • HDL hypothesis: In developer (Liponex) studies, PI raised HDL negative charge and cholesterol excretion in rabbits (Burgess 2003) and increased liver-cell secretion of apoA-I (apolipoprotein A-I, HDL’s main protein) via MAPK (mitogen-activated protein kinase, a signaling cascade) (Hopewell 2008) and PPAR-α (peroxisome proliferator-activated receptor alpha, a fat-burning gene switch); the linoleic acid chains, not inositol, were required (Pandey 2008).
  • Inositol donor: Digestion releases some free inositol.
  • Competing view: Some gene variants that raise HDL-C were not linked to lower heart attack risk (Voight 2012), and in liver cells lacking MBOAT7 (an enzyme loading arachidonic acid, a signaling omega-6 fatty acid, onto PI), fast PI turnover fed fat synthesis (Tanaka 2021).
  • Pharmacology: Pancreatic phospholipase A2 cleaves PI to lysophosphatidylinositol (PI minus one fatty acid), which is absorbed and re-esterified; PI lacks a single receptor target and enters lipoproteins and membranes. No human half-life exists; intravenous PI’s lipoprotein effects faded within 24 hours in rabbits (Stamler 2000). In vitro, PI barely inhibited CYP450 (liver drug-metabolizing) enzymes or UGT1A1 (a drug- and bilirubin-conjugating enzyme) (Pandey 2008).

Historical Context & Evolution

PI’s original role was as a research object and a minor component of soy and egg lecithin used as food emulsifiers, not as a supplement. In 1953, Hokin and Hokin found that stimulating pancreas tissue sharply increased phosphate turnover in its phospholipids (Hokin 1953), a response later traced mainly to PI. Michell proposed in 1975 that inositol-lipid breakdown couples cell-surface receptors to cell responses (Michell 1975); IP3 and DAG were identified as the messengers in the 1980s, and PI3K became central to insulin and growth signaling in the 1990s.

Interest in PI for health optimization came from two directions. Between 2000 and 2008, researchers at the University of Ottawa Heart Institute led by Daniel Sparks, working through Liponex, reported faster cholesterol clearance in rabbits (Stamler 2000) and higher HDL-C after two weeks in humans (Burgess 2005). The company’s formulation, CRD5, then missed its HDL-C endpoint in a 2007 trial (Liponex press release), and no later results were published. In parallel, Japanese nutrition groups (Yanagita, Nagao, Shirouchi) reported that dietary PI lowered liver fat (Shirouchi 2008) and cholesterol (Shirouchi 2009) in rats.

Opinion then shifted for reasons outside PI. Genetic studies indicated that some inherited routes to higher HDL-C do not lower heart attack risk (Voight 2012), weakening the original rationale, while free inositol built its own evidence base in metabolic medicine. Neither development tested PI itself, so its standing remains open rather than settled.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: of the four developer trials reported as completed in the developers’ review (Pandey 2008), only two small ones have public lipid results, without clinical outcomes or independent replication.

Medium 🟩 🟩

No benefit reaches Medium: the single positive PI trial is contradicted by the developer’s larger trial, and the remaining human data concern free inositol, a different compound.

Low 🟩

Higher HDL Cholesterol and Lower Triglycerides ⚠️ Conflicted

In a 2-week trial of 16 adults with normal lipids, soy PI with food raised HDL-C (Burgess 2005). A trial in 56 patients with abnormal lipids found no significant rise at 1–3 g/day (Liponex press release). Net: dose, population or formulation may explain the gap; no reliable benefit is established.

Magnitude: HDL-C rose 13% (2.8 g/day) and 18% (5.6 g/day) from baseline, and triglycerides fell 36% at 5.6 g/day, in the fed groups after 2 weeks, no control group (Burgess 2005). In the later trial, mean HDL-C rose less than 5% from baseline at 1 g and 3 g/day, not statistically significant and not compared between groups; the source does not report the placebo group’s change (Liponex press release); a later review describes the same trial as showing a significant 5% rise (Pollex 2008).

Better Glucose Control and Insulin Sensitivity

Digestion releases inositol from PI, and a meta-analysis of 20 randomized trials of inositol compounds found lower fasting glucose and insulin resistance (Miñambres 2019). The evidence is indirect: free inositol rather than PI. In rats, dietary PI relieved high insulin levels (Shirouchi 2008).

Magnitude: For inositol, not PI, fasting glucose was 0.44 mmol/L lower than control (95% CI, the range likely to contain the true effect, 0.23–0.65) and HOMA-IR (homeostatic model assessment of insulin resistance) 1.96 units lower (95% CI 1.30–2.62) (Miñambres 2019); no PI trial has measured glucose outcomes.

Speculative 🟨

Protection Against Fatty Liver

In Zucker rats, a 2% PI diet for 4 weeks prevented liver fat buildup, raised adiponectin (a fat-cell hormone that improves insulin action) and lowered liver injury markers (Shirouchi 2008). Basis: animal data only.

Faster Cholesterol Clearance

Intravenous PI in rabbits raised biliary cholesterol secretion 21-fold and fecal cholesterol 2.5-fold (Burgess 2003); dietary PI increased fecal bile acids in rats (Shirouchi 2009). Basis: animal data only.

Less Immune-Driven Liver Injury

Mice fed PI for 6 weeks produced fewer inflammatory cytokines (immune signaling proteins) and resisted liver injury from concanavalin A (a plant protein that triggers immune liver attack) (Inafuku 2013). Basis: animal data only.

Slower Aging via Inositol Signaling

PI’s head group, myo-inositol, extended worm lifespan through PIP2 and daf-18 (the worm version of PTEN, a gene that restrains PI3K signaling), with effects also reported in mice (Shi 2020). Basis: animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No variant is known to modify PI’s lipid response. Carriers of the MBOAT7 rs641738 T allele have impaired PI remodeling and more fatty liver (Mancina 2016), a plausible but untested subgroup for the liver hypothesis.
  • Baseline biomarkers: A review reports that in the developer’s 12-week trial over 20% of patients had HDL-C rises above 10%, mostly when baseline HDL-C was below 0.9 mmol/L (about 35 mg/dL) (Pollex 2008).
  • Sex: No sex-specific benefit data exist; women typically start with higher HDL-C, which may leave less room for an HDL-related effect.
  • Pre-existing conditions: Insulin resistance and fatty liver are where inositol and animal PI data suggest the most room for benefit (Miñambres 2019); people with healthy metabolism have no data suggesting benefit.
  • Food intake: PI changed lipids significantly only when taken with food (Burgess 2005).
  • Age: No trial enrolled older adults specifically or reported age subgroups, so responses at the older end of the target range are unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: of the four developer trials reported as completed in the developers’ review (Pandey 2008), only two have public adverse-event data, without independent replication.

Medium 🟥 🟥

Gastrointestinal Intolerance at Higher Doses ⚠️ Conflicted

In the developer’s later dose-ranging trial (Liponex), gastrointestinal adverse events caused enough withdrawals at 5 g/day to suspend that arm (Liponex press release), as a review also reports (Pollex 2008). Lecithin, PI’s source material, is listed as causing diarrhea, nausea and abdominal fullness (Drugs.com lecithin side effects page). In contrast, 2.8–5.6 g/day for 2 weeks was well tolerated by all 16 adults (Burgess 2005), and the developers’ review calls PI safe above 5 g (Pandey 2008). Net: intolerance appears dose- and duration-dependent, emerging around 5 g/day over several weeks.

Magnitude: Completers were 50 on placebo, 49 at 1 g, 38 at 3 g and 11 at 5 g/day; adverse-event rates per arm, including placebo, were not reported (Liponex press release). The 2-week trial had no placebo group and reported no adverse-event rate (Burgess 2005).

Low 🟥

Allergic Reactions in Soy-Sensitive People ⚠️ Conflicted

Soy PI is extracted from soy lecithin, which can carry trace soy protein; case reports describe food allergy to soy lecithin (Palm 1999). Evidence is indirect (lecithin, not purified PI). In a randomized crossover trial, 1 of 20 soy-allergic children reacted to lecithin (Gholmie 2020). Net: reactions appear rare.

Magnitude: 1 of 20 children with non-IgE (not mediated by the allergy antibody immunoglobulin E) soy allergy reacted to 1.5 g/day soy lecithin versus 5 during placebo (Gholmie 2020); case reports give no rate.

Speculative 🟨

Promotion of Growth Signaling in Cancer

PI feeds PIP3 production by PI3K, and its digestion product lysophosphatidylinositol activates GPR55 (a receptor that drives tumor-cell growth), per a review (Falasca 2016). No study links dietary PI to cancer; mechanistic basis only.

Liver Fat from Increased PI Turnover

In liver cells lacking MBOAT7, accelerated PI breakdown supplied diacylglycerol for triglyceride synthesis and fat buildup (Tanaka 2021). Whether dietary PI does this is untested; mechanistic and animal basis only.

Risk-Modifying Factors

  • Genetic polymorphisms: MBOAT7 rs641738 T-allele carriers, whose PI remodeling is impaired, have higher fatty liver risk (Mancina 2016); whether extra dietary PI burdens these livers is unknown. No pharmacogenetic variant affecting PI handling is known.
  • Baseline biomarkers: Soy-specific IgE or a positive soy skin test marks higher allergy risk; elevated liver enzymes at baseline warrant caution given the untested PI-turnover concern (Tanaka 2021).
  • Sex: No sex-specific adverse-event data exist for PI; neither trial reported tolerance by sex.
  • Pre-existing conditions: Soy allergy, irritable bowel syndrome or other gastrointestinal disorders (multi-gram doses), bipolar disorder treated with lithium (inositol-related mechanism; an inositol add-on trial found no average difference from placebo in mood-score change, Eden Evins 2006) and active cancer (theoretical growth-signaling concern) raise risk.
  • Age: Neither PI trial reported participants over 65; older adults taking several medications face untested interaction and tolerability profiles.

Key Interactions & Contraindications

Documented interactions:

  • Food (meals): PI’s effects on HDL-C and triglycerides were significant only in participants who took it with food (Burgess 2005). Consequence: loss of the lipid effect when taken fasting. Taking each dose with a meal avoids this.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Fibrates (fenofibrate, gemfibrozil; triglyceride-lowering drugs): PI activated PPAR-α, the fibrate target, in liver cells (Pandey 2008); additive triglyceride lowering and HDL-C change are possible. A lipid panel 4–8 weeks after combining shows the net effect.
  • Statins (atorvastatin, rosuvastatin; cholesterol-lowering drugs): Additive lipid-modifying effects through separate pathways; minimal in-vitro CYP450 inhibition makes a blood-level interaction unlikely (Pandey 2008). A follow-up lipid panel shows the net effect.
  • Glucose-lowering drugs (metformin, insulin, glipizide): Inositol released from PI may add insulin-sensitizing effects, theoretically increasing hypoglycemia (low blood glucose) risk. Glucose checks during the first weeks detect this.
  • Bile acid sequestrants (bile acid-binding resins that lower cholesterol; cholestyramine, colesevelam): These resins bind lipids in the gut and may reduce PI absorption, lowering any effect. Separating doses by at least 4 hours avoids overlap.
  • Orlistat (over-the-counter Alli): Additive gastrointestinal adverse effects, as orlistat causes fat malabsorption and oily stools and multi-gram PI doses cause gastrointestinal upset. Keeping PI at low doses limits overlap.
  • PI3K inhibitors (alpelisib, idelalisib): These cancer drugs block PI3K, which uses PI-derived PIP2; extra substrate could theoretically oppose their effect on tumor growth signaling. Pausing PI during treatment avoids the question.
  • Mood stabilizers (lithium, valproate): Lithium is thought to act by depleting inositol, so inositol released from PI could blunt it; an add-on trial of free inositol, not PI, found no average difference from placebo in mood-score change (Eden Evins 2006). Mood tracking detects change.
  • Inositol supplements (myo-inositol, D-chiro-inositol): Additive inositol load and additive glucose-lowering effects. Counting total inositol intake across products limits excess.
  • Other phospholipids (lecithin, phosphatidylcholine, phosphatidylserine): Additive phospholipid load raises gastrointestinal upset risk. Counting total phospholipid grams per day limits this.
  • Niacin, fish oil, berberine: Additive HDL-C-raising, triglyceride-lowering or glucose-lowering effects, which confound attribution of lipid changes to PI. Adding one agent at a time allows attribution.
  • Aerobic exercise and alcohol intake: Both raise HDL-C by separate mechanisms, confounding lipid monitoring. Keeping both stable during a PI trial period preserves interpretability.

Populations who should avoid Phosphatidylinositol:

  • People with confirmed IgE-mediated soy allergy (positive soy-specific IgE or skin test with clinical reactions), based on case reports of food allergy to soy lecithin (Palm 1999).
  • People with active cancer treated with PI3K inhibitors: inferred from PI’s role as the source of PI3K substrate and from lysophosphatidylinositol–GPR55 signaling; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Dose ceiling below 5 g/day: The 5 g/day arm was halted for gastrointestinal withdrawals while most participants completed 1–3 g/day (Liponex press release); staying at or below 3 g/day limits gastrointestinal intolerance.
  • Meals and slow titration: Starting at 1 g/day with food and increasing by 1 g every 1–2 weeks reduces diarrhea, nausea and abdominal fullness.
  • Soy-allergy screening: People with known soy allergy confirming tolerance with an allergist before use prevents allergic reactions to residual soy protein (Palm 1999).
  • Liver enzyme check: ALT (alanine aminotransferase, a liver injury marker) at baseline and 12 weeks addresses the untested PI-turnover liver-fat concern; a rise above the laboratory’s upper limit prompts stopping.
  • Avoidance during cancer therapy: Not using PI during treatment of PI3K-driven cancers avoids the theoretical growth-signaling risk.
  • Mood-stabilizer monitoring: Tracking mood and drug levels in people on lithium or valproate who use PI prevents unnoticed loss of mood-stabilizer effect.

Therapeutic Protocol

Each dose below is cited to its source; other parameters (timing, titration, splitting) reflect common practice.

  • Short-term trial regimen: 2.8 g or 5.6 g/day of soy PI with food for 2 weeks, the only peer-reviewed human regimen (Burgess 2005).
  • 12-week trial regimen: 1 g or 3 g/day in capsules after a dietary lead-in; 5 g/day was suspended for gastrointestinal intolerance (Liponex press release; also a review, Pollex 2008).
  • Lecithin approach: Some users take de-oiled soy lecithin granules; an 11 g serving (one heaping tablespoon) declares 1.0 g PI, the lowest trial dose, plus more phosphatidylcholine (Life Extension label). No study has tested this approach.
  • Inositol alternative: Free myo-inositol delivers the head group directly at 1.2–4 g/day in current trials (NCT03875755, NCT07770711) but lacks PI’s linoleic acid chains.
  • Popularizers: No physician, clinic or longevity practitioner has published a PI protocol; all human regimens come from the developer Liponex and its founder, Daniel Sparks (Burgess 2005).
  • Time of day: No study compared timings; because the lipid effect required food, doses are taken with the main meals.
  • Half-life: No human half-life is published; in rabbits, intravenous PI’s lipoprotein effects faded within 24 hours (Stamler 2000), consistent with daily dosing.
  • Single or split dose: Splitting the daily amount across two or three meals matches the food requirement and spreads the gastrointestinal load.
  • Genetic polymorphisms: No genotype is known to alter PI dosing; MBOAT7 rs641738 carriers are a theoretical subgroup for liver effects (Mancina 2016).
  • Sex differences: No sex-specific dosing or response data exist; neither trial reported results by sex.
  • Age: Trials reported no data for adults over 65; the lowest tested dose, 1 g/day (Liponex press release), is the usual starting point given tolerability uncertainty.
  • Baseline biomarkers: Baseline HDL-C below 0.9 mmol/L (about 35 mg/dL) was associated with larger HDL-C rises in the developer’s trial, per a review (Pollex 2008).
  • Pre-existing conditions: Low HDL-C was the developer’s target condition; insulin resistance and fatty liver are rationales from inositol and animal data only (Miñambres 2019).

Discontinuation & Cycling

  • Lifelong or short-term: PI has been tested only for 2–12 weeks; it is used as a time-limited trial judged by lipid response, not as established lifelong therapy.
  • Withdrawal effects: None reported; lipid changes are expected to revert after stopping, although reversal was never measured.
  • Tapering: Not required; no rebound effect has been described.
  • Cycling: No data support cycling; a lipid panel after 8–12 weeks determines whether continued use shows measurable value.

Sourcing and Quality

  • Purified PI is scarce: Highly purified soy PI is sold mainly as a laboratory reagent not intended for human consumption; consumer products are mostly lecithin or phospholipid complexes with PI as a minor declared component.
  • PI content on the label: Products stating PI in milligrams per serving, not only “lecithin” or “phospholipids”, allow dose comparison, since the PI content of lecithins varies widely.
  • Third-party testing: USP (United States Pharmacopeia) or NSF International certification verifies label content and contaminant limits; neither has a PI-specific standard.
  • Fatty acid stability: Soy PI is rich in linoleic acid, which oxidizes; opaque sealed packaging, refrigeration after opening and a clear expiry date limit rancidity.
  • Allergen and processing: Soy-derived products carry an allergen statement; extraction solvent (often hexane) and genetically modified soy status vary by manufacturer and are disclosed by transparent brands.
  • Reputable brands: No brand sells purified PI at trial doses, and the developer’s CRD5 formulation is unavailable; de-oiled soy lecithin with a declared PI content, such as Life Extension Lecithin (about 1.0 g PI per serving, Life Extension label), is the closest consumer option.

Practical Considerations

  • Time to effect: Lipid changes appeared within 2 weeks in the positive trial (Burgess 2005), whereas the 12-week trial found no significant change (Liponex press release), so 8–12 weeks is a practical evaluation window.
  • Confusing related compounds: PI is distinct from inositol, phosphatidylserine and phosphatidylcholine; most “inositol” products contain free myo-inositol, not PI.
  • Fasted dosing: Taking PI without food removed the significant lipid effect in the only positive trial (Burgess 2005).
  • Equating an HDL-C rise with lower risk: Some gene variants that raise HDL-C were not linked to lower heart attack risk (Voight 2012), so an HDL-C change alone does not demonstrate cardiovascular benefit.
  • Regulatory status: In the US, lecithin is affirmed as generally recognized as safe as a food ingredient (21 CFR 184.1400); PI products are marketed as dietary supplements.
  • Cost and access: Lecithin is inexpensive, and de-oiled granules supply about 1 g PI per serving, but purified PI is not available as a consumer supplement, making the 3–5.6 g/day trial regimens hard to replicate.

Interaction with Foundational Habits

  • Sleep: None known; no study measured sleep with PI. Free inositol has been explored for sleep, but trial-level PI supplies comparatively little free inositol, and evening dosing with meals is not known to disrupt sleep.
  • Nutrition: Potentiating: the lipid effect required food (Burgess 2005). Dietary PI comes from soybeans, legumes, eggs and grains; Japanese meals supply about 0.12 g/day of PI plus phosphatidylserine (Shirouchi 2018), far below trial doses.
  • Exercise: Indirect: aerobic training independently raises HDL-C and improves insulin sensitivity, overlapping PI’s proposed effects; no study tested PI with exercise and no effect on muscle adaptation is known. Stable training during a PI trial keeps lipid results interpretable.
  • Stress management: None known; PI has no documented effect on cortisol or the stress response. Inositol has been studied for anxiety, but at doses far above what PI supplies.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a fasting lipid panel including HDL-C and triglycerides, apoA-I, fasting glucose and insulin for HOMA-IR, and ALT establish personal reference values. For people with soy allergy, allergist clearance precedes use in common practice. Two baseline lipid measurements improve the ability to detect a true change, because HDL-C varies from day to day.

Ongoing monitoring: Lipids and apoA-I are rechecked at 2–4 weeks, matching the positive trial, and again at 12 weeks, matching the null trial. Glucose, insulin and ALT are rechecked at 12 weeks, then every 6–12 months if PI is continued. Success is a sustained HDL-C rise or triglyceride fall beyond baseline variation without gastrointestinal or allergic symptoms; absence of change by 12 weeks defines non-response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
HDL-C ≥40 mg/dL men, ≥50 mg/dL women; ≥60 mg/dL protective (NCEP ATP III) Expected to change: main claimed effect Source: NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III). Conventional reference range >39 mg/dL (lab-dependent). Fasting optional; pair with apoA-I.
Triglycerides <150 mg/dL (NCEP ATP III) Expected to change: fell in the 2-week trial Source: NCEP ATP III. Conventional reference range <150 mg/dL. 9–12 hour fast; no alcohol for 24 hours before.
ApoA-I About 94–178 mg/dL men, 101–199 mg/dL women (standard reference range) Expected to change: rose in the 2-week trial Ranges are laboratory-specific; same lab each time; draw with the lipid panel.
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change: indirect, inositol-based 8-hour fast; morning draw; pair with fasting insulin.
HOMA-IR No established target; track change from own baseline Expected to change: indirect, inositol-based Calculated from fasting glucose and insulin; same lab and time of day each draw.
ALT 7–55 U/L (standard reference range) Safety check: a rise above the upper limit stops use Pair with AST (aspartate aminotransferase, a second liver enzyme); avoid strenuous exercise 48 hours before.

Qualitative markers:

  • Gastrointestinal comfort: stool consistency, bloating, nausea, abdominal fullness.
  • Allergic signs: itching, hives, lip or throat swelling.
  • Mood stability: relevant for people taking lithium or valproate.
  • Post-meal energy and appetite: subjective tracking; no PI data exist.

Emerging Research

  • No registered PI trials: A ClinicalTrials.gov search found no registered trial of oral PI; “phosphatidylinositol” records concern PI3K-inhibitor drugs. The second CRD5 phase I/II trial, anticipated for early 2008, has no published results (Liponex press release).
  • MYO-GDM inositol trial: NCT03875755 randomizes 1,080 women with gestational diabetes to 1.2 g/day myo-inositol or placebo; primary endpoint insulin need; active, completion January 2027. A positive result strengthens the indirect inositol–glucose rationale; a null result weakens it.
  • Inositol versus metformin in PCOS: NCT07770711 is recruiting 90 women with polycystic ovary syndrome (PCOS, a hormonal disorder with insulin resistance) for 4 g/day myo-inositol or metformin with diet; primary endpoint HOMA-IR at 2 months; completion September 2027. Positive results support, null results undercut, the glucose item.
  • Inositol alone and HDL-C: A meta-analysis of 14 trials found inositol lowered triglycerides and LDL (low-density lipoprotein) cholesterol but not HDL-C (Tabrizi 2018), consistent with the developer’s view that linoleic acid chains drive any HDL effect (Pandey 2008).
  • HDL function rather than level: Human studies measuring cholesterol efflux capacity (HDL’s ability to pull cholesterol out of cells) would test the rabbit mechanism directly; genetic evidence that some HDL-C-raising variants do not lower heart attack risk (Voight 2012) weakens HDL-C-only endpoints.
  • Cancer-signaling safety: Research on the lysophosphatidylinositol–GPR55 axis in tumors (Falasca 2016) could reveal a safety signal relevant to dietary PI if digestion raises circulating lysophosphatidylinositol.
  • Aging models: Inositol’s lifespan extension through PIP2 and PTEN in worms, with slower health decline in mice (Shi 2020) has not been tested with PI; such studies could strengthen or weaken the longevity rationale.

Conclusion

Phosphatidylinositol is a natural building block of cell membranes and the parent of signaling fats that carry insulin and growth messages inside cells; as a supplement it comes mainly from soybeans. Its case for health and longevity rests on a short, small human study in which it raised “good” cholesterol, on animal studies in which it reduced liver fat and sped cholesterol removal, and on its partial release of inositol, a related compound with its own research on blood sugar control.

The human evidence is thin and conflicted. Both human trials with published results were run by the company developing it, which had a direct financial interest in favorable results, and that company’s own larger and longer trial did not confirm the cholesterol effect. Blood sugar benefits rest on inositol research rather than on this compound, and the liver, cholesterol-removal and aging benefits come from animals only. Genetic research also indicates that some natural ways of having higher “good” cholesterol do not lower heart attack risk.

Known risks appear modest at lower intakes: digestive upset became a problem at the highest amount tested, and people with soy allergy may react. Concerns about feeding growth signals in cancer or adding to liver fat remain theoretical.

For a health-focused adult willing to experiment, the compound is biologically plausible and generally well tolerated in moderate amounts, but no consistent evidence shows that the amounts studied change an outcome that matters for health or lifespan.

Top - Benefits - Risks - Protocol